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MaOBJECTIVES This report describes the immediate, 1-, and 5-year follow-up results of the U.S. Food and Drug
Administration Continued Access clinical trial of the GORE HELEX Septal Occluder (W. L. Gore & Associates, Inc.,
Flagstaff, Arizona) for closure of secundum atrial septal defect.
BACKGROUND The trial was conducted between May 2003 and August 2006 to allow continued enrollment in a trial
of the investigational device during review of data from the Pivotal Trial. Devices with hydrophilic coating on the
expanded polytetraﬂuoroethylene to improve echocardiographic visualization were ﬁrst used in this trial.
METHODS A total of 137 devices were implanted in 137 patients at 13 US institutions. Evaluations were scheduled at 1, 6,
and 12 months for the initial trial and at 36 and 60 months for a later extension of the trial in those who consented to
longer term evaluations.
RESULTS Twelve-month follow-up was completed on 122 of 126 patients with implantations, and 5-year follow-up on
83 of 95 patients who agreed to the trial extension. The overall clinical success rate was 96.7%, and the major adverse
event rate 3.6%. Wire frame fractures were seen in 11.7% of patients with no clinical symptoms. A trivial, clinically
insigniﬁcant leak was seen, or could not be ruled out, in 26.6% of patients at the 5-year evaluation, but no clinically
signiﬁcant leaks were seen. No patient experienced an erosion or sudden catastrophic event.
CONCLUSIONS The immediate, 1-, and 5-year follow-up outcomes of the Continued Access clinical trial continue to
demonstrate that the GORE HELEX Septal Occluder is a safe and effective transcatheter occluder for repair of ostium
secundum atrial septal defect. (J Am Coll Cardiol Intv 2014;7:905–12) © 2014 by the American College of Cardiology
Foundation.T he GORE HELEX Septal Occluder (HELEX)(W.L. Gore and Associates, Inc., Flagstaff,Arizona) was developed for closure of secun-
dum atrial septal defects (ASDs) in the early 1990s.
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906modiﬁed with the addition of a hydrophilic
coating on the Gore-Tex to improve echocar-
diographic visualization for the Continued
Access study.
The HELEX is a circular double-disk device
composed of a single ﬂexible nitinol wire
frame helically shaped and draped with a
thin membrane of expanded polytetra-ﬂuoroethylene (ePTFE). The device is repositionable
during its deployment and is retrievable even after
initial release from the delivery system by a retrieval
chord or string that tethers the occluder to the de-
livery system until ﬁnal release.METHODS
The Continued Access trial was begun in May 2003 at
13 clinical centers (Table 1).
Each center obtained approval from its institu-
tional review board. Informed consent (and assent
where applicable) was obtained by the principal
investigator from each patient. The trial was
approved by the U.S. Food and Drug Administration
and was sponsored by W.L. Gore and Associates, Inc.,
the manufacturer of the device.
Inclusion criteria were an ostium secundum ASD
with a balloon occlusion diameter of #22 mm, right
heart volume overload on echocardiography or as
indicated by a Qp/Qs $1.5:1, adequate rim in $75% of
the circumference of the defect, and femoral venous
access suitable to accommodate the 9-French delivery
system. Exclusion criteria included signiﬁcant co-
morbidity with anticipated cardiac surgery or catheter
intervention, uncontrolled arrhythmia, arrhythmias
requiring electrophysiological study, systemic or1 Patient Enrollment by Site
Site City
Hope Children’s Hospital Oak Lawn/C
’s Health Care Egleston–Emory Atlanta
’s Hospital and Regional Medical Center Seattle
’s Hospital of Iowa Iowa City
’s Hospital of Oakland Oakland
’s Hospital of Philadelphia Philadelphia
’s Hospital of San Diego San Diego
’s Hospital Los Angeles Los Angeles
d Clinic Foundation Cleveland
hildren’s Hospital Denver
iversity Medical Center Durham
ildren’s Hospital Miami
y of Texas Southwestern Medical Center Dallas
. of subjects implanted
wn are number (%).inherited conditions that would signiﬁcantly increase
patient risk of major morbidity or mortality during the
term of the study, history of stroke, pregnancy or
lactation, contraindications to antiplatelet therapy,
pulmonary artery hypertension with greater than half
systemic pulmonary artery pressure or resistance
index $5 Wood units, signiﬁcant atrial septal aneu-
rysm, the presence of multiple defects requiring >1
device, and atrial septal thickness >8 mm.
For the Continued Access study, a diagnostic cath-
eterization was performed for determination of shunt
and resistances. Stop-ﬂow balloon sizing was per-
formed in standard fashion. Although current recom-
mendations are to use a device 2 times the stop-ﬂow
diameter, ratios as low as 1.6 times the stop-ﬂow
diameter were allowed in this study. The selected de-
vice was loaded into the delivery catheter per manu-
facturer’s instructions. The delivery catheter was then
introduced into a short 9-French sheath. The delivery
catheter was advanced under ﬂuoroscopic guidance
across the ASD. The device was conﬁgured with 1 disk
on either side of the septum using ﬂuoroscopic and
either transesophageal or intracardiac echocardio-
graphic guidance. A detailed description of the im-
plantation procedure was previously published (3).
Pre-procedure evaluation included history and
physical, electrocardiogram, and transthoracic echo-
cardiogram. The same evaluations were performed
pre-hospital discharge and again at 1, 6, 12, 36, 48,
and 60 months post-implantation. Fluoroscopy of the
device was performed at 6, 12, and 60 months to
assess for wire frame fracture.
OUTCOME MEASURES. The primary endpoint of the
Continued Access study was clinical success, a com-
posite variable evaluating safety and efﬁcacy, atInvestigator(s) Device Count
hicago Alexander Javois, MD 23 (16.8)
Robert Vincent, MD 5 (3.6)
Thomas Jones, MD 21 (15.3)
Thomas Fagan, MD 12 (8.8)
Ziad Saba, MD 3 (2.2)
Jonathan Rome, MD 24 (17.5)
Frank Ing, MD 6 (4.4)
Sarah Bedran, MD 2 (1.5)
Larry Latson, MD 12 (8.8)
Kak-Chen Chan, MD 1 (0.7)
J. Rhodes/J. Delaney, MD 11 (8.0)
Evan Zahn, MD 16 (11.7)
Thomas Zellers, MD 1 (0.7)
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90712 months. It was deﬁned as 1) all atrial defects either
completely occluded or any possible residual shunt
judged to be clinically insigniﬁcant, 2) the absence of
repeat procedure to the target ASD, and 3) the
absence of major complication(s). Secondary end-
points included the individual component variables
of safety and efﬁcacy. Safety outcomes for the study
included assessment of all device-related and
procedure-related adverse events through the 12-
month follow-up. Determinations of major versus
minor adverse events were adjudicated by the Data
and Safety Monitoring Board. The Data and Safety
Monitoring Board comprised 4 uninvolved physicians
(2 cardiac surgeons and 2 interventional cardiologists)
and a biostatistician. Major complications were
deﬁned as events related to the device or procedure
that resulted in readmission to the hospital or per-
manent damage or deﬁcit. Speciﬁc types of events
were pre-designated to be recorded as major adverse
events. These included additional intervention such
as a pericardial or pleural drainage tube, new
arrhythmia requiring intervention, device emboliza-
tion, endocarditis, fracture of the device resulting in
surgery and/or clinical sequelae, perforation of car-
diovascular structures by the device or delivery sys-
tem, a thrombotic/thromboembolic event resulting in
clinical sequelae, permanent loss of arterial pulse,
retroperitoneal bleed or groin hematoma, trans-
fusion, or repeat procedure to the target defect.
Events to be classiﬁed as minor adverse events
included device fracture resulting in no clinical
sequelae, noncomplicated pleural or pericardial
effusion that resolved without intervention or with
nonsteroidal anti-inﬂammatory drugs and diuretics,
transient pain or weakness due to peripheral nerve
stretching while under anesthesia, arrhythmias
requiring no extended pacing or medication, tempo-
rary loss of arterial pulse, superﬁcial hematoma, mi-
graines, transfusion, and fever.
Efﬁcacy outcome included assessment of defect
closure at each of the follow-up visits and was eval-
uated in terms of residual shunt. A description of
residual defect was determined by the principal
investigator at each site, but ﬁnal determination for
endpoints was by an echocardiography core labora-
tory. Residual shunt was categorized as clinically
signiﬁcant, clinically insigniﬁcant, or completely
occluded. Device artifact and technical factors made
precise measurement of residual shunt size with a
single number untenable. Clinically signiﬁcant leak
was deﬁned as any of the following: 1) residual left-
to-right shunt with evidence of right heart volume
overload that would likely require repeat interven-
tion as judged by the echocardiographer; 2) a Qp/Qs $1.5:1 as measured by cardiac catheterization; 3)
clinical sequelae related to the leak; and 4) hemody-
namically signiﬁcant, deﬁned as failure to meet the
criteria for hemodynamically insigniﬁcant. Clinically
insigniﬁcant leak was deﬁned as a deﬁnite or possible
small leak associated with all of the following criteria:
1) normalization of ventricular septal motion; 2)
noticeable variation in right ventricular end-diastolic
dimension with respiration; 3) signiﬁcant decrease in
right ventricular size as determined by comparison of
equivalent images of the right ventricle before and
after device placement evaluating for decrease in the
M-mode echocardiographic measurement of the right
ventricle and no diastolic ﬂattening of the ventricular
septal contour in the short-axis view; and 4) the
apparent effective diameter of any residual leak
or leaks as determined by evaluation of both
2-dimensional echocardiographic and color Doppler
views judged to be approximately #3 mm and
clearly <6 mm. There could be no clinical sequelae for
a small leak to be considered an insigniﬁcant leak.
STATISTICAL ANALYSIS. Statistics presented are
descriptive. No statistical tests of hypotheses were
conducted.RESULTS
A total of 137 patients underwent successful implan-
tation at 13 sites between May 2003 and August 2006.
Patient, ASD, and HELEX device characteristics are
provided in Table 2. Implantation and follow-up
compliance for these 137 patients are shown in
Table 3. Of the 137 patients who underwent device
implantation, 11 were lost to follow-up at 1 year. Of
the remaining 126 patients, 122 (96.8%) completed the
12-month evaluation. At 5 years, 83 of 95 of the pa-
tients (87.4%) who consented to the extended study
completed the evaluation (42 patients withdrew from
the study or were lost to follow-up).
Clinical success, a composite of safety and efﬁcacy,
at 12 months was high at 96.7%. Major adverse events
are detailed in Table 4. Most events were seen within
the ﬁrst 30 days of implantation. Beyond that time,
events were mostly incidental device wire frame
fracture without clinical signiﬁcance. Five major
adverse events were seen: 2 device embolizations,
both on day 1, that were successfully retrieved by
transcatheter technique; 1 wire frame fracture inci-
dentally discovered at 61 days post-implantation with
the device retrieved by transcatheter technique; 1
wire frame fracture associated with an echocardio-
graphic ﬁnding suggesting 2 additional ASDs and so
the device was removed on day 1,175 with surgical
TABLE 3 Patient Follow-up Compliance by Interval
Device Training Pre-discharge
Total no. of patients* 137
Patients who discontinued before interval 0
Patients not reached at start of interval 0
Patients available for interval follow-up† 137
No. with follow-up evaluation 136 (99.3)
Transthoracic or transoesophageal echocardiography 136 (99.3)
Electrocardiography completed 125 (91.2)
Fluoroscopy completed‡ 0 (0.0)
No. with visit pending§ 0 (0.0)
No. without follow-up evaluation 1 (0.7)
Discontinued in interval before visitk 1 (0.7)
Interval visit was outside window 0 (0.0)
Missed visit¶ 0 (0.0)
Values shown are number (%). Percentages use patients available for interval follow-up
discharge, days 0 to 2; 1 month, days 15 to 46; 6 months, days 151 to 244; 12 months, days
of patients with a successful HELEX device placement. †Patients available for interval foll
interval and patients not reached at start of interval. ‡Fluoroscopy required at 6, 12, an
analysis. kPatients available for follow-up visit at start of interval, but discontinued in win
interval in next time interval. ¶Patients completed study interval window with no visit r
TABLE 2 Patient Demographic Characteristics
Device Count
No. of subjects who underwent implantation 137
Sex
Male 54 (39.4)
Female 83 (60.6)
Subject ethnicity
White or Caucasian 92 (67.2)
Black or African American 8 (5.8)
Hispanic or Latino 17 (12.4)
Asian 7 (5.1)
Other 10 (7.3)
Unknown 3 (2.2)
Patient age, yrs
No. 137
Mean (SD) 9.5 (10.4)
Median 5.8
Range 0.8–58.4
Weight, kg
No. 137
Mean (SD) 30.7 (22.7)
Median 19.7
Range 6.9–114.0
Body surface area
No. 137
Mean (SD) 0.98 (0.48)
Median 0.79
Range 0.33–2.40
Defect size from balloon sizing, mm
No. of patients 134*
Mean (SD) 13 (3.0)
Median 13.0
Range 5–22.0
Values shown are number (%) unless otherwise indicated. *The balloon sizing for 3
subjects was not recorded/documented at the time of implantation.
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908closure of all defects; and 1 unrelated death on day
820 (graft–versus-host disease after bone marrow
transplantation).
Wire frame fracture data are shown in Table 5. A
fracture was discovered in 8.5% of patients who
underwent ﬂuoroscopic evaluation in the ﬁrst 12
months and in 5.2% of patients from 13 to 60
months. No fractures were seen in 15- and 20-mm
devices. There was an increasing incidence of frac-
ture as device size increased: 2.1% of 25-mm de-
vices, 26.7% of 30-mm devices, and 45.5% of 35-mm
devices. The majority (10/14) of fractures were
noted within the ﬁrst 12 months. Thirteen of 14
fractures were incidentally discovered at scheduled
ﬂuoroscopic evaluations. The one fracture detected
outside the scheduled ﬂuoroscopic evaluation was
found in a device noted to have excessive mobility
of the right atrial disk on routine echocardiography.
All other fractures were discovered incidentally, and
no fracture was associated with any clinical signs.
Two patients with fractures underwent treatment; 1
demonstrated increased mobility and 1 had a
persistent large shunt with additional defects. Both
were removed electively. There were no apparent
clinical sequelae related to the other fractures,
consistent with the experience reported in the
pivotal study (4).
Residual shunting data are shown in Table 6. The
echocardiographic core laboratory was instructed to
classify studies in which all ideal views were not
obtainable (could not deﬁnitely rule out a leak) into
the appropriate clinically signiﬁcant or insigniﬁcant
leak category. This policy was used to ensure that the1
Month
6
Months
12
Months
36
Months
60
Months
137 137 137 137 137
3 9 11 33 42
0 0 0 0 0
134 128 126 104 95
121 (90.3) 112 (87.5) 122 (96.8) 72 (69.2) 84 (88.4)
121 (90.3) 111 (86.7) 122 (96.8) 71 (68.3) 83 (87.4)
117 (87.3) 106 (82.8) 118 (93.7) 69 (66.3) 82 (86.3)
0 (0.0) 95 (74.2) 109 (86.5) 4 (3.8) 74 (77.9)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
13 (9.7) 16 (12.5) 4 (3.2) 32 (30.8) 11 (11.6)
0 (0.0) 0 (0.0) 1 (0.8) 3 (2.9) 2 (2.1)
0 (0.0) 0 (0.0%) 0 (0.0) 1 (1.0) 3 (3.2)
13 (9.7) 16 (12.5) 3 (2.4) 28 (26.9) 6 (6.3)
as the denominator (unless otherwise noted). Follow-up windows are as follows: pre-
245 to 548; 36 months, days 913 to 1,276; 60 months, days 1,642 to 2,006. *Number
ow-up equal the total number of patients minus patients who discontinued before the
d 60 months. §Patients currently in study interval, but no visit reported at time of
dow and before visit. These patients are included in patients who discontinued before
eported.
TABLE 4 Number of Patients by Category of Major Adverse Events
Days 0–30
Post-procedure
Day 31–Month 18
Post-procedure
Months 19–60
Post-procedure Overall
No. of patients evaluable for safety 137 133 109 137
Patients with $1 major adverse event 2 (1.5) 1 (0.8) 2 (1.8) 5 (3.6)
Device related
No. of patients 2 (1.5) 1 (0.8) 1 (0.9) 4 (2.9)
Cardiac 2 (1.5) — — 2 (1.5)
Embolization (post-procedure) 2 (1.5) — — 2 (1.5)
Device (HELEX Septal Occluder
(W. L. Gore & Associates, Inc.,
Flagstaff, Arizona))
— 1 (0.8) 1 (0.9) 2 (1.5)
Device removal related to fracture — 1 (0.8),
unstable device
1 (0.9),
additional defects
2 (1.5)
Other (not device or not procedure related)
No. of patients — — 1 (0.9) 1 (0.7)
Other — — 1 (0.9) 1 (0.7)
Death s/p bone marrow transplantation — — 1 (0.9) 1 (0.7)
Values shown are number (%).
s/p ¼ status post.
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909reported incidence of possible leaks could not be
underestimated. No echocardiograms were deemed
unsuitable for detecting larger leaks or requiring
repeat evaluation. By deﬁnition, clinically insigniﬁ-
cant leak indicated that right heart chamber sizes
were normal and no further intervention was
required. One clinically signiﬁcant leak was seen at
12 months. Unfortunately, this patient was lost to
further follow-up. In the cohort of patients who
consented to 5-year follow-up, there were no residual
signiﬁcant leaks. No residual shunting was seen with
the 15-mm device. With increasing device size,TABLE 5 Summary of Wire Frame Fractures: Overall and by Device S
Overall 15
Patients with successful delivery 137 5
6-Month follow-up visit 114 5
Fluoroscopy completed* 98 5
Patients with fracture(s)*† 7 (7.1) 0
12-Month follow-up visit 122 5
Fluoroscopy completed 109 4
Patients with fracture(s)† 3 (2.8) 0
6- or 12-Month follow-up visit 128 5
Fluoroscopy completed* 118 5
Patients with fracture(s)*† 10 (8.5) 0
Post–12-month follow-up visit 109 5
Fluoroscopy completed* 77 4
Patients with fracture(s)*† 4 (5.2) 0
Overall 129 5
Fluoroscopy completed* 120 5
Patients with fracture(s)*† 14 (11.7) 0
Values shown are number or number (%). *Includes 2 fractures identiﬁed before 6-
ﬂuoroscopy.however, clinically insigniﬁcant leaks became more
frequent. At 5-year follow-up, 21.1% of 20-mm de-
vices, 26.7% of 25-mm, 26.3% of 30-mm, and 57.1% of
35-mm were found to have clinically insigniﬁcant
leaks (Tables 7 and 8). The only residual clinically
signiﬁcant leak was seen in a patient with a 35-mm
device. At 12 months, complete occlusion was seen
in 70.1% and a clinically insigniﬁcant leak in 29.1%.
The data were nearly identical at 5 years post-
implantation with 58 of 79 patients (73.4%) with to-
tal occlusion and 21 of 79 (26.6%) with a clinically
insigniﬁcant leak (Table 6).ize (mm)
20 25 30 35
31 55 32 14
24 46 29 10
19 38 26 10
0 1 (2.6) 4 (15.4) 2 (20.0)
27 48 29 13
26 42 26 11
0 0 1 (3.8) 2 (18.2)
29 51 30 13
27 46 29 11
0 1 (2.2) 5 (17.2) 4 (36.4)
25 42 26 11
20 24 22 7
0 0 3 (13.6) 1 (14.3)
30 51 30 13
27 47 30 11
0 1 (2.1) 8 (26.7) 5 (45.5)
month follow-up. †Denominator for percentage is number of subjects completing
TABLE 6 Residual Defect Status
12 Months
(Days 245–548)
24 Months
Optional
(Days 549–912)
36 Months
(Days 913–1,276)
48 Months
Optional
(Days 1,277–1,641)
60 Months
(Days 1,642–2,006)
Patients with successful delivery 137 137 137 137 137
Patients with core laboratory review 117 16 65 20 79
Completely occluded 82 (70.1) 8 (50.0) 52 (80.0) 12 (60.0) 58 (73.4)
Clinically insigniﬁcant leak 34 (29.1) 8 (50.0) 13 (20.0) 8 (40.0) 21 (26.6)
Clinically signiﬁcant leak 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Patients missing core laboratory review 20 121 72 117 58
Discontinued study before evaluation 12 (60.0) 28 (23.1) 35 (48.6) 37 (31.6) 44 (75.9)
Core laboratory review not completed 8 (40.0) 93 (76.9) 37 (51.4) 80 (68.4) 14 (24.1)
Values shown are number or number (%).
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910Clinical success endpoints at 12, 36, and 60
months are shown in Table 9. At 5 years, 54 of 137
patients were not participating in the extended trial
or were lost to follow-up. Protocol-scheduled
follow-up was extended from 1 year post-procedure
to 5 years post-procedure as a separately consented
study at the time of U.S. Food and Drug Adminis-
tration approval. Many subjects chose not to
continue participation in the extended follow-up. Of
the remaining 83 patients, 79 (95.2%) met criteria
for clinical success.
DISCUSSION
Compared with the Pivotal Study of the HELEX (5),
Continued Access study patients were younger (9.5
years vs. 12.4 years) and smaller (30.7 kg vs. 35.6 kg).
All investigators reported higher conﬁdence in
placing the new hydrophilically coated device due to
improved echocardiographic imaging. The hydro-
philic coating on the ePTFE enhanced ultrasound
penetration of the device with markedly less echo-
cardiographic reﬂection artifact (6). The smaller pa-
tient size in the Continued Access study is likely aTABLE 7 Residual Defect Status: 12-Month Echocardiography Core La
15
No. of patients with successful delivery 5
No. of patients with core laboratory review 5
Completely occluded 4 (80.0)
Clinically insigniﬁcant leak 1 (20.0)
Clinically signiﬁcant leak 0 (0.0)
Patients missing core laboratory review 0
Discontinued study before evaluation
Core laboratory review not completed
Values shown are number or number (%).result of better device visualization as well as
enhanced learning curve over time.
Overall, only 4 device-related major adverse
events were detected: 2 embolizations within 24 h
of implantation (successfully retrieved in the cath-
eter laboratory and subsequently closed by trans-
catheter technique) and 2 device fractures resulting
in removal. The fractured device removed in the
catheter laboratory at 61 days demonstrated an
excessively mobile right atrial disk. Despite com-
plete closure of the ASD, it was thought that the
long-term outcome of this device was uncertain,
and so the decision was made to remove it. The
second device was removed because there were 2
additional ASDs that required treatment that would
be best addressed surgically (protocol did not allow
additional devices). None of these 4 major adverse
events resulted in clinical manifestations (all pa-
tients were asymptomatic before the decision to
intervene).
STUDY LIMITATIONS. First, this study was not
designed for comparison with other devices or tech-
niques, nor was it designed as a randomizedboratory Review
Device Size, mm
20 25 30 35
31 55 32 14
26 47 27 12
18 (69.2) 32 (68.1) 23 (85.2) 5 (41.7)
8 (30.8) 15 (31.9) 4 (14.8) 6 (50.0)
0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3)
5 8 5 2
2 (40.0) 6 (75.0) 3 (60.0) 1 (50.0)
3 (60.0) 2 (25.0) 2 (40.0) 1 (50.0)
TABLE 8 Residual Defect Status: 60-Month Echo Core Lab Review
Device Size, mm
15 20 25 30 35
Patients with successful delivery 5 31 55 32 14
Patients with core laboratory review 4 19 30 19 7
Completely occluded 4 (100.0) 15 (78.9) 22 (73.3) 14 (73.7) 3 (42.9)
Clinically insigniﬁcant leak 0 (0.0) 4 (21.1) 8 (26.7) 5 (26.3) 4 (57.1)
Clinically signiﬁcant leak 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Patients missing core laboratory review 1 12 25 13 7
Discontinued study before evaluation 1 (100.0) 8 (66.7) 22 (88.0) 8 (61.5) 5 (71.4)
Core laboratory review not completed 0 (0.0) 4 (33.3) 3 (12.0) 5 (38.5) 2 (28.6)
Values shown are number or number (%).
TABLE 9 Clinical Success Endpoint Through 12-Month Follow-up
12
Months
36
Months
60
Months
Evaluable patients with successful delivery 137 137 137
Clinical success endpoint
Patients evaluated 120 69 83
Clinical success 116 (96.7) 65 (94.2) 79 (95.2)
Clinical failure 4 (3.3) 4 (5.8) 4 (4.8)
Major device/procedure adverse event 3 (2.5) 4 (5.8) 4 (4.8)
Adverse event
Signiﬁcant leak on ﬁnal core
laboratory evaluation
1 (0.8) 0 (0.0) 0 (0.0)
Patients not evaluated 17 68 54
Lost to follow-up before evaluation 9 32 40
Final defect evaluation missing 8 36 14
Values shown are number or number (%).
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911evaluation. Second, the study has relatively small
numbers so it is not powered to detect small differ-
ences in the outcome parameters. Third, exclusion
criteria may not reﬂect the entire population in which
devices may be used after approval.
CONCLUSIONS
This report focuses on both the short- and long-term
safety and efﬁcacy data for the U.S. FDA Continued
Access Clinical Trial of the HELEX. More than 96% of
patients with successful implantation met the pri-
mary endpoint of clinical success with no more than a
trivial residual shunt, normalization of right ventric-
ular size, and no major adverse event. In particular,
there were no erosions, perforations, allergic re-
actions, or arrhythmias requiring treatment. The
major adverse events seen were 2 early asymptomatic
device embolizations treated by transcatheter
retrieval and 2 elective removals of devices from the
atrial septum (1 possible device instability and 1
associated with additional defects).
One patient had a clinically signiﬁcant residual
shunt at intermediate follow-up, and no clinically
signiﬁcant leaks were seen in patients who consented
to follow-up for 5 years. Although this Continued
Access study included patients with implantation
procedures using a device-to-defect ratio as small as
1.6:1 and defects as large as 22 mm, subsequent
analysis of combined data from the Feasibility,
Pivotal, and Continued Access Studies of the HELEX
have shown that the small residual leaks are more
likely to occur with device size–to–defect size
ratios <2:1 and in patients with defects >18 mm (7).
Based on those ﬁndings, current instructions for use
recommend device size–to–defect size ratios $2:1 and
limitation of use to defects #18 mm.
Wire frame fractures were seen in 11.7% of patients,
but all were asymptomatic, with 92% being detectedonly by radiographic evaluation including ﬂuoros-
copy. It has become evident that simple detection of a
wire frame fracture does not require additional treat-
ment or investigation; thus, ﬂuoroscopic evaluations
are no longer recommended in the instructions for
use. No change in follow-up has been recommended
for simple detection of a wire frame fracture, but
abnormal mobility of a portion of the device as seen on
echocardiography warrants radiographic evaluation
and close follow-up. Embolization of a portion of the
device has not been observed, likely because the entire
wire frame except for the locking mechanism is
ensheathed by an ePTFE membrane. In the worldwide
experiencewith the HELEX, there have been 2 patients
reported with asymptomatic perforations of a mitral
valve leaﬂet discovered by echocardiography (4,8).
The recommended schedule of echocardiographic
evaluations appears to be adequate for evaluation of
this possibility. To date, there have been no reported
cases of late sudden catastrophic events (such as
erosion) associated with the HELEX. The shape and
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912relative “softness” of this device likely contribute to
this excellent safety record. The larger the device, the
more likely it was that a wire frame fracture would
develop.
A relatively high incidence of clinically insigniﬁ-
cant residual leak (or inability to rule out a trivial
leak) was seen at 1 year and persisted at 5-year
follow-up. Because right heart chamber dimensions
normalized, patients with these leaks were
considered to be similar to the w20% of the normal
population who can be shown to have a patent
foramen ovale or small interatrial communica-
tion by careful echocardiographic evaluation. No
changes in antiplatelet treatment or endocarditis
prophylaxis precautions have been recommendedfor patients with possible or deﬁnite insigni-
ﬁcant leaks. Recommended changes for device
size–to–defect size ratio and maximal ASD size will
likely result in a lower incidence of such possible
trivial leaks.
Immediate, 1-, and 5-year follow-up of the multi-
center trial indicates that the device is a safe and
effective alternative to the repair of an ostium
secundum ASD.
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